Source: http://www.academia-net.org/profil/prof-phd-valeria-poli/1187248
Timestamp: 2019-04-26 13:00:40+00:00

Document:
Maritano, D., Sugrue, M.L., Tininini, S., Dewilde, S., Strobl, B., Fu, XP, Murray-Tait, V., Chiarle, R. and Poli, V. The STAT3 isoforms, a and b, play unique and specific roles. (2004) Nat. Immunol. 5, 401 – 409.
Vallania, F., Schiavone, D., Dewilde, S., Pupo, E., Garbay, S., Calogero, R., Pontoglio, M., Provero, P. and Poli, V. Genome-Wide Discovery of Functional Transcription Factor Binding Sites by Comparative Genomics: the Case of Stat3. (2009) Proc. Natl. Acad. Sci. USA 106:5117 – 22.
Pensa S, Watson CJ and Poli V. Stat3 and the Inflammation/Acute Phase Response in Involution and Breast Cancer. (2009) J Mammary Gland Biol Neoplasia 14:121 – 9.
Schiavone D, Dewilde S, Vallania F, Turkson J, Di Cunto F and Poli V. The RhoU/Wrch1 Rho GTPase gene is a common transcriptional target of both the gp130/Stat3 and Wnt-1 pathways. (2009) Biochem J. 421:283 – 92.
Barbieri I, Quaglino E, Maritano D, Pannellini T, Riera L, Cavallo F, Forni G, Musiani P, Chiarle R and Poli V. Stat3 is required for anchorage independent growth and metastasis but not for mammary tumor development downstream of the ErbB-2 oncogene. (2010) Molecular Carcinogenesis 49:114 – 20.
Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, Voster A, Turkson J, Cavallo F, Watson CJ, Provero P, Musiani P and Poli V. Constitutively active Stat3 enhances Neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. (2010) Cancer Res. 70:2558 – 67.
Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, Gough DJ, Turkson J, Levy DE, Watson CJ, Wieckowski MR, Provero P, Pinton P and Poli V. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. (2010) Aging 2:823 – 842.
Kreuzaler PA, Staniszewska AD, Li W, Omidvar N, Kedjouar B, Turkson J, Poli V, Flavell RA, Clarkson RWE, and Watson CJ. Stat3 controls lysosomal mediated cell death in vivo. (2011) Nature Cell Biology 13:303 – 309.
Schiavone D, Avalle L, Dewilde S, Poli V. The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3. (2011) FEBS Lett. 585, 2455 – 2460.
Demaria M, Misale S, Giorgi C, Miano V, Camporeale A, Campisi J, Pinton P and Poli V. STAT3 can serve as a hit in the process of malignant transformation of primary cells. 2012, Cell Death and Differentiation 19: 1390-1397; advanced online publication, Mar 9, 2012. doi: 10.1038/cdd.2012.20.
Camporeale A, Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? (2012) Frontiers in Bioscience 17:2306-2326.
Demaria M and Poli V. Pro-malignant properties of STAT3 during chronic inflammation. (2012) Oncotarget 3:359 – 360.
Camporeale A, Marino F, Papageorgiou A, Carai P, Fornero S, Fletcher S, Page BDG, Gunning P, Forni M, Chiarle R, Morello M, Jensen O, Levi R, Heymans S, Poli V. STAT3 activity is necessary and sufficient for the development of immune-mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. (2013) EMBO Mol. Medicine (Epub ahead of print, 5 MAR 2013), DOI: 10.1002/emmm.201201876.
Molineris I, Schiavone D, Rosa F, Matullo G, Poli V* and Provero P. Identification of functional cis-regulatory polymorphisms in the human genome. (2013) Human Mutation, Feb 19. doi: 10.1002/humu.22299 [Epub ahead of print] * co-corresponding author.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.